phosphonoacetic acid has been researched along with Malignant Melanoma in 14 studies
Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.
phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted parallel phase II trials of cimetidine as a single agent and the combination N-phosphonacetyl-L-aspartate (PALA) plus L-alanosine among 40 previously untreated patients with biopsy-proven, measurable disseminated malignant melanoma." | 9.06 | Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma. ( Chang, M; Creagan, ET; Cullinan, SA; Ebbert, L; Mailliard, JA; Morton, RF; Veeder, MH, 1987) |
| "Twenty-two patients with advanced malignant melanoma were entered in a pilot study receiving combination chemotherapy with PALA, vindesine, and cisplatin (PVP)." | 7.67 | PALA, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma. A pilot study. ( Kleeberg, UR; Voigt, H, 1984) |
| " In the human melanoma cell lines IGR3 and M5 the main metabolite of 5FU was 5-fluorouridine, while in the murine B16 melanoma only a small amount of 5-fluorouridine was formed." | 7.67 | Separation of several 5-fluorouracil metabolites in various melanoma cell lines. Evidence for the synthesis of 5-fluorouracil-nucleotide sugars. ( Lankelma, J; Laurensse, E; Leyva, A; Peters, GJ; Pinedo, HM, 1984) |
| "We conducted parallel phase II trials of cimetidine as a single agent and the combination N-phosphonacetyl-L-aspartate (PALA) plus L-alanosine among 40 previously untreated patients with biopsy-proven, measurable disseminated malignant melanoma." | 5.06 | Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma. ( Chang, M; Creagan, ET; Cullinan, SA; Ebbert, L; Mailliard, JA; Morton, RF; Veeder, MH, 1987) |
| "Twenty-two patients with advanced malignant melanoma were entered in a pilot study receiving combination chemotherapy with PALA, vindesine, and cisplatin (PVP)." | 3.67 | PALA, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma. A pilot study. ( Kleeberg, UR; Voigt, H, 1984) |
| " To test this hypothesis we examined the effects of PALA and nitrobenzylthioinosine (NBMPR) alone and in combination on B16 melanoma cells in vitro using a clonogenic assay and in vivo using growth delay." | 3.67 | Antitumor activity of N-phosphonacetyl-L-aspartic acid in combination with nitrobenzylthioinosine. ( Erlichman, C; Vidgen, D, 1984) |
| " In the human melanoma cell lines IGR3 and M5 the main metabolite of 5FU was 5-fluorouridine, while in the murine B16 melanoma only a small amount of 5-fluorouridine was formed." | 3.67 | Separation of several 5-fluorouracil metabolites in various melanoma cell lines. Evidence for the synthesis of 5-fluorouracil-nucleotide sugars. ( Lankelma, J; Laurensse, E; Leyva, A; Peters, GJ; Pinedo, HM, 1984) |
| "Another solid tumor, Ridgway osteogenic sarcoma, which is sensitivie to many established chemotherapeutic agents, did not respond to PALA." | 1.26 | Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase. ( Goldin, A; Inouye, T; Johnson, RK; Stark, GR, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (92.86) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Peters, GJ | 2 |
| Laurensse, E | 2 |
| Leyva, A | 3 |
| Pinedo, HM | 3 |
| Kleeberg, UR | 2 |
| Mulder, JH | 1 |
| Rümke, P | 1 |
| Thomas, D | 1 |
| Rozencweig, M | 1 |
| Voigt, H | 1 |
| Erlichman, C | 3 |
| Vidgen, D | 1 |
| Lankelma, J | 2 |
| Donehower, RC | 1 |
| Speyer, JL | 1 |
| Klecker, R | 1 |
| Chabner, BA | 1 |
| Appel, H | 1 |
| Smith, P | 1 |
| Karle, JM | 1 |
| Anderson, LW | 1 |
| Cysyk, RL | 1 |
| Johnson, RK | 2 |
| Swyryd, EA | 1 |
| Stark, GR | 3 |
| Inouye, T | 1 |
| Goldin, A | 1 |
| McMillan, TJ | 1 |
| Kalebic, T | 1 |
| Hart, IR | 1 |
| Cillo, C | 1 |
| Dick, JE | 1 |
| Ling, V | 1 |
| Hill, RP | 1 |
| Morton, RF | 1 |
| Creagan, ET | 1 |
| Cullinan, SA | 1 |
| Mailliard, JA | 1 |
| Ebbert, L | 1 |
| Veeder, MH | 1 |
| Chang, M | 1 |
| Chan, TC | 1 |
| Young, B | 1 |
| King, ME | 1 |
| Taetle, R | 1 |
| Howell, SB | 1 |
1 trial available for phosphonoacetic acid and Malignant Melanoma
| Article | Year |
|---|---|
Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma.
Topics: Alanine; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cimetidine; Drug Evaluation; | 1987 |
13 other studies available for phosphonoacetic acid and Malignant Melanoma
| Article | Year |
|---|---|
Fluctuations in phosphoribosyl pyrophosphate levels in monolayer tumor cell lines. Effects of drugs.
Topics: Animals; Aspartic Acid; Buffers; Cell Line; Cytological Techniques; Fibroblasts; Humans; Melanoma; M | 1984 |
N-(phosphonacetyl)-L-aspartate (PALA) in advanced malignant melanoma: a phase II trial of the EORTC Malignant Melanoma Cooperative Group.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Drug Eruptions; Drug Evaluation; Female; Humans; | 1982 |
PALA, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma. A pilot study.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Bone Marrow; C | 1984 |
Antitumor activity of N-phosphonacetyl-L-aspartic acid in combination with nitrobenzylthioinosine.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic A | 1984 |
Separation of several 5-fluorouracil metabolites in various melanoma cell lines. Evidence for the synthesis of 5-fluorouracil-nucleotide sugars.
Topics: Animals; Aspartic Acid; Cell Line; Cells, Cultured; Chromatography; Deoxyuracil Nucleotides; Fluorod | 1984 |
Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Drug Administration Schedule; | 1982 |
Inhibition of cell growth by N-(phosphonacetyl)-L-aspartate in human and murine cells in vitro.
Topics: Animals; Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartic Acid; Cell Division; Cell L | 1981 |
Serum uridine levels in patients receiving N-(phosphonacetyl)-L-aspartate.
Topics: Antimetabolites, Antineoplastic; Aspartic Acid; Colonic Neoplasms; Drug Evaluation; Humans; Melanoma | 1980 |
Effects of N-(phosphonacetyl)-L-aspartate on murine tumors and normal tissues in vivo and in vitro and the relationship of sensitivity to rate of proliferation and level of aspartate transcarbamylase.
Topics: Animals; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Cells, Cult | 1978 |
Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase.
Topics: Animals; Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamyl Phosphate; D | 1976 |
High frequency of double drug resistance in the B16 melanoma cell line.
Topics: Amides; Animals; Antineoplastic Agents; Aspartic Acid; Cell Line; Colony-Forming Units Assay; Drug R | 1990 |
Generation of drug-resistant variants in metastatic B16 mouse melanoma cell lines.
Topics: Animals; Aspartic Acid; Cell Line; Drug Resistance; Gene Amplification; Mathematics; Melanoma; Metho | 1987 |
Modulation of the activity of PALA by dipyridamole.
Topics: Animals; Aspartic Acid; Biological Transport; Cell Line; Colonic Neoplasms; Dipyridamole; Drug Inter | 1985 |